ORNBV Orion Oyj Class B

Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel

Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel



ORION CORPORATION 

STOCK EXCHANGE RELEASE – CHANGES BOARD/MANAGEMENT/AUDITORS

19 DECEMBER 2024 at 19.00 EET

        

Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel

Olli Huotari, Senior Vice President responsible for Corporate Functions organization of the Orion Group and Secretary to the Board of Directors of Orion Corporation, and a member of the Executive Management Board of the Orion Group informed earlier of his decision to leave Orion on 31 May 2025. Mikko Kemppainen has been appointed as General Counsel and Secretary to the Board of Directors of Orion Corporation, and a member of the Executive Management Board of the Orion Group as of 1 June 2025.



The appointed General Counsel Mikko Kemppainen will be responsible for the following of Olli Huotari’s responsibility areas: Compliance, Intellectual Property Rights, Legal Affairs, and Public Affairs. Other responsibility areas of Huotari will be transferred to other members of the Executive Management Board of the Orion Group as of June 1, 2025.



Mikko Kemppainen holds a Master of Laws (Trained at the Bench) degree. He joined Orion as a Legal Counsel in 2006 and has been the Head of Legal Affairs at Orion Corporation since 2007. Prior to joining Orion, Kemppainen worked as Associate and Senior Associate at Hannes Snellman Attorneys Ltd during 2000−2006.

President and CEO Liisa Hurme says:



“I would like to sincerely thank Olli Huotari for his long and distinguished career at Orion in various roles. We have worked closely together for years, and he has been the most reliable and pleasant colleague in every situation.



Liisa Hurme continues:



“I warmly welcome Mikko Kemppainen to the Orion Executive Management Board to implement our growth strategy together. I am glad that the best candidate for the position was found within the company. I believe that Mikko’s long experience with Orion and from the pharmaceutical industry will be valuable in his new position. I look forward to working with him in the executive management board.”



“I’m honored by this appointment and excited about the opportunity to join Orion’s Executive Management Board. Orion is a fine company and I’m looking forward to continue the work for its growth and success in my new role”, says Mikko Kemppainen.

Olli Huotari says:



“I have always appreciated and been very grateful for all the positions and career Orion has offered to me. Orion is an excellent company with great people. I wish the company, its stakeholders, and especially the Orionees all the best and success also in the future!“

ANNEX: CV of Mikko Kemppainen



Mikko Kemppainen

Born 1972

Finnish citizen

Education:



Master of Laws, University of Lapland, Finland, 1998



Career:



Paul Henriksson Attorneys at Law

Assisting lawyer, 1998−1999



District Court of Tornio, Finland

Bench Training, 1999−2000

District Court Judge, 2000



Hannes Snellman Attorneys Ltd.        

Associate, Senior Associate 2000−2006



Orion Corporation

Legal Counsel, 2006−2007

Head of Legal Affairs, 2007−

Orion Corporation

Liisa Hurme

President and CEO 
Terhi Ormio

Vice President, Communications

                                                 

Contact person:



Liisa Hurme, President and CEO

Tel. + 358 50 966 2874



Contact person for the media:



Terhi Ormio, Vice President, Communications

Tel. +358 50 966 4646





Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo, Finland



Orion is a globally operating Finnish pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to EUR 1,190 million and the company had about 3,600 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

Attachment



EN
19/12/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Orion Oyj Class B

 PRESS RELEASE

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securi...

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS6 March 2026 at 16.00 EET          Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly and indirectly by BlackRock, Inc. and its funds increased on 5 March 2026 above five (5) per cent of Orion C...

 PRESS RELEASE

Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoit...

Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoitus (BlackRock, Inc.) ORION OYJ        PÖRSSITIEDOTE / SUURIMMAT OSAKKEENOMISTAJAT -TIEDOTE        6.3.2026 KLO 16.00          Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoitus (BlackRock, Inc.) Orion Oyj on saanut Arvopaperimarkkinalain 9. luvun 5 §:n mukaisen ilmoituksen, jonka mukaan BlackRock, Inc.:n ja sen rahastojen suoraan ja välillisesti omistamien Orionin osakkeiden osuus on 5.3.2026 ylittänyt viisi (5) prosenttia Orion Oyj:n kaikista osakkeista. BlackRock, Inc.:n ja sen rahastojen osu...

 PRESS RELEASE

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securi...

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS5 MARCH 2026 at 15.00 EET          Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly and indirectly by BlackRock, Inc. and its funds decreased on 4 March 2026 below five (5) per cent of Orion C...

 PRESS RELEASE

Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoit...

Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoitus (BlackRock, Inc.) ORION OYJ        PÖRSSITIEDOTE / SUURIMMAT OSAKKEENOMISTAJAT -TIEDOTE        5.3.2026 KLO 15.00          Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoitus (BlackRock, Inc.) Orion Oyj on saanut Arvopaperimarkkinalain 9. luvun 5 §:n mukaisen ilmoituksen, jonka mukaan BlackRock, Inc.:n ja sen rahastojen suoraan ja välillisesti omistamien Orionin osakkeiden osuus on 4.3.2026 alittanut viisi (5) prosenttia Orion Oyj:n kaikista osakkeista. BlackRock, Inc.:n ja sen rahastojen osu...

 PRESS RELEASE

Orion Group Financial Statement documents 2025 and Remuneration Report...

Orion Group Financial Statement documents 2025 and Remuneration Report published ORION CORPORATION STOCK EXCHANGE RELEASE – ANNUAL FINANCIAL REPORT 27 FEBRUARY 2026 at 11.05 EET         Orion Group Financial Statement documents 2025 and Remuneration Report published Orion Group's Financial Statement documents for 2025 have been published. The documents are available in Finnish and English on the Company's website at and are attached to this release. Financial Statement documents include the company’s Financial Statements, the Report by the Board of Directors, the Sustainability Stateme...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch